^ Jump up to: a b c Boggs, Douglas L; Nguyen, Jacques D; Morgenson, Daralyn; Taffe, Michael A; Ranganathan, Mohini (September 6, 2017). "Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol". Neuropsychopharmacology. 43 (1): 142–154. doi:10.1038/npp.2017.209. ISSN 0893-133X. PMC 5719112. PMID 28875990.
As you may know, industrial hemp and marijuana come from the same genus of flowering plant– cannabis. The term “genus” essentially refers to a sub-family of plants and not a single species. This means that there may be multiple types of the cannabis plant, which are all cannabis but have remarkable differences. So, in terms of scientific classification, multiple species can exist within a single genus, and that’s exactly the case with cannabis.
Laboratory evidence indicated that cannabidiol may reduce THC clearance, increasing plasma concentrations which may raise THC availability to receptors and enhance its effect in a dose-dependent manner. In vitro, cannabidiol inhibited receptors affecting the activity of voltage-dependent sodium and potassium channels, which may affect neural activity. A small clinical trial reported that CBD partially inhibited the CYP2C-catalyzed hydroxylation of THC to 11-OH-THC. Little is known about potential drug interactions, but CBD-mediates a decrease in clobazam metabolism.